Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$6.87 -0.00%

-$0.00 today

Market cap
$865.72M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 3.97M

Average 2.58M

VSTM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Verastem, Inc.NASDAQ: VSTM

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $2.05M rose 14.4% year over year, behind the +26.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.

Context

  • Stock-based compensation amounted to 30.4% of revenue in FY2025, down 43.0 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +14.4% toward the trailing-twelve-month pace of +26.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.05M+1.0% QoQ
Last fiscal yearDec 2025
$9.4M+28.1% YoY
LTMMar 2026
$9.66M+26.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.4%——
1 year+28.1%——
3-year CAGR+15.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.4M USD
Year-over-year change
+28.1%
4-year CAGR
+5.1%

Stock-Based Compensation vs competitors

How VSTM compares with its peers on the latest reported figures

  • VSTM's LTM Mar 2026 stock-based compensation of $9.66M is the 6th largest of the 11 companies compared; the peer median is $6.67M.
  • Its year-over-year change of +26.4% is the 4th highest of 10, against a peer median of -11.0%.
  • Stock-based compensation amounts to 19.5% of revenue for VSTM, versus a peer median of 38.3%.
VSTM Competitors Peer median
Stock-Based Compensation for VSTM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$25.38M +66.4%——
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M -153.0%+30.1%11.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M -43.8%-14.0%46.7%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$13.11M -11.0%+88.9%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M -60.8%-22.0%60.3%
VSTMVerastem, Inc.LTM Mar 2026$9.66M +26.4%+15.9%19.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M +42.2%—26.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.99M +19.7%+10.2%1140.6%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$3.82M +1696.3%——
ANLAdlai Nortye Ltd.LTM Jun 2024$1.94M ——29.9%
IMRXImmuneering CorporationLTM Mar 2026$1.52M -69.5%——
Peer median (excluding VSTM) $6.67M-11.0%+10.2%38.3%

Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.2M)(73.81M)(87.37M)(130.64M)(209.47M)
Depreciation & Amortization72K(36K)62K26K728K
Deferred Income Tax00000
Stock-Based Compensation7.71M6.05M5.86M7.34M9.4M
Change in Working Capital584K3.9M(957K)3.72M26M
Accounts Receivables(277K)485K31K(200K)(8.81M)
Inventory0000(1.83M)
Accounts Payables623K2.6M2.28M(3.16M)8.42M
Other Working Capital238K816K(3.27M)7.08M28.23M
Other Non-Cash Items9.33M228K(4.06M)14.78M35.83M
Operating Cash Flow(53.5M)(63.67M)(86.46M)(104.77M)(137.51M)
Capital Expenditures(196K)00(28K)0
Acquisitions (Net)9.33M0000
Purchases of Investments(86.44M)(17.82M)(96.45M)00
Sales of Investments86.73M84M52M60M29K
Other Investing Activities(9.33M)005K(29K)
Investing Cash Flow87K66.19M(44.45M)59.97M(9.62M)
Debt Repayment024.15M14.62M(150K)32.42M
Common Stock Issued6.72M27.35M91.42M14.22M230.88M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities162K282K57K40.71M0
Financing Cash Flow6.89M51.78M134.19M54.78M263.31M
Effect of Forex Changes00000
Net Change in Cash(46.53M)54.3M3.29M9.98M116.17M
Free Cash Flow(53.7M)(63.67M)(86.46M)(104.8M)(137.51M)

Verastem, Inc.

NASDAQ:VSTM

Intrinsic Alpha fair value

Locked

Current Price

$6.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.